同种异体CD70靶向CAR-T治疗晚期肾细胞癌:I期TRAVERSE试验结果
TRAVERSE I期试验评估同种异体CD70靶向CAR-T产品ALLO-316治疗ICI和靶向治疗耐药的晚期透明细胞肾细胞癌。Ib期客观缓解率25.0%,CD70肿瘤比例评分≥50%者达31.3%。ALLO-316安全性可控并显示抗肿瘤活性。
要点
- ALLO-316在CD70阳性ccRCC中安全性可控,Ib期ORR为25.0%。
- CD70 TPS≥50%的Ib期患者ORR达31.3%。
- ≥3级CRS、ICANS和IEC-HLH样综合征发生率分别为2.0%、0%和6.0%。
核心结论
- ALLO-316在CD70阳性ccRCC中安全性可控并显示鼓舞人心的抗肿瘤活性,TRAVERSE试验为同种异体CAR-T治疗实体瘤提供概念验证。
研究设计与样本
- 患者接受淋巴细胞清除后输注ALLO-316,Ia期评估剂量及含氟达拉滨/环磷酰胺(FC)方案联合或不联合抗CD52抗体ALLO-647。
- 主要终点为剂量限制性毒性(DLT)和不良事件(AE)。
主要发现
- 中位既往治疗4线,中位随访28.8个月。
- DLT发生于2例接受ALLO-647的患者:3级自身免疫性肝炎和5级心源性休克。
- ≥3级CRS、ICANS和IEC-HLH样综合征发生率分别为2.0%、0%和6.0%。
- 多数≥3级AE为血液学毒性:中性粒细胞减少62.0%、白细胞计数降低54.0%、贫血36.0%。
- Ib期患者接受FC和80×10^6 CAR-T细胞,总体ORR 17.4%,Ib期25.0%,Ib期CD70 TPS≥50%者31.3%。
临床怎么用
- ALLO-316为ICI和靶向治疗耐药的CD70阳性ccRCC提供潜在同种异体CAR-T选项。
- 治疗相关毒性以血液学为主,需关注CRS、IEC-HLH样综合征及ALLO-647相关DLT。
- CD70 TPS≥50%可能提示更高缓解概率,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment options for clear cell renal cell carcinoma (ccRCC) refractory to immune checkpoint inhibitors (ICIs) and targeted therapy are needed. ALLO-316 is an allogeneic chimeric antigen receptor (CAR) T-cell product that targets CD70-expressing ccRCC and resists immune rejection by targeting and eliminating patients' CD70+ alloreactive T cells. METHODS: In the phase Ia/b TRAVERSE trial (ClinicalTrials.gov identifier: NCT04696731), patients with advanced ccRCC resistant to ICIs and vascular endothelial growth factor receptor-targeted therapy received lymphodepletion and ALLO-316 following a modified 3 + 3 design. Phase Ia evaluated ALLO-316 dose and fludarabine/cyclophosphamide (FC)-based lymphodepletion with/without the anti-CD52 antibody, ALLO-647. Additional patients were enrolled in phase Ib to confirm the expansion regimen identified in phase Ia. Primary end points were dose-limiting toxicities (DLTs) and adverse events (AEs). RESULTS: Fifty-one patients were enrolled (phase Ib, n = 23). Patients received a median of four prior lines of therapy. The median follow-up was 28.8 months. DLTs occurred in two patients who received ALLO-647 (grade 3 autoimmune hepatitis; grade 5 cardiogenic shock). Grade ≥3 cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome occurred in 2.0%, 0%, and 6.0% of patients, respectively. Most grade ≥3 AEs were hematologic (neutropenia 62.0%; white blood cell count decreased 54.0%; anemia 36.0%). In phase Ib, patients received FC and 80 × 106 CAR T cells. The objective response rate was 17.4% overall, 25.0% in phase Ib patients and 31.3% in phase Ib patients with CD70 tumor proportion score ≥50%. CONCLUSION: ALLO-316 had manageable safety and encouraging antitumor activity in CD70-positive ccRCC. The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors.
引用
- Srour SA, Chahoud J, Drakaki A, et al. Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. J Clin Oncol. 2026. PMID: 42447427. doi:10.1200/JCO-26-00388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。